SG11201705559RA - Formulation of mk2 inhibitor peptides - Google Patents
Formulation of mk2 inhibitor peptidesInfo
- Publication number
- SG11201705559RA SG11201705559RA SG11201705559RA SG11201705559RA SG11201705559RA SG 11201705559R A SG11201705559R A SG 11201705559RA SG 11201705559R A SG11201705559R A SG 11201705559RA SG 11201705559R A SG11201705559R A SG 11201705559RA SG 11201705559R A SG11201705559R A SG 11201705559RA
- Authority
- SG
- Singapore
- Prior art keywords
- formulation
- inhibitor peptides
- peptides
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101190P | 2015-01-08 | 2015-01-08 | |
| PCT/US2016/012650 WO2016112292A1 (en) | 2015-01-08 | 2016-01-08 | Formulation of mk2 inhibitor peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201705559RA true SG11201705559RA (en) | 2017-08-30 |
Family
ID=56356475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201705559RA SG11201705559RA (en) | 2015-01-08 | 2016-01-08 | Formulation of mk2 inhibitor peptides |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10087225B2 (en) |
| EP (1) | EP3242886A4 (en) |
| JP (1) | JP2018502860A (en) |
| KR (1) | KR20170102900A (en) |
| CN (1) | CN107406489A (en) |
| AU (1) | AU2016205125A1 (en) |
| BR (1) | BR112017014737A2 (en) |
| CA (1) | CA2972916A1 (en) |
| HK (1) | HK1246807A1 (en) |
| MX (1) | MX2017008994A (en) |
| RU (1) | RU2017128077A (en) |
| SG (1) | SG11201705559RA (en) |
| WO (1) | WO2016112292A1 (en) |
| ZA (1) | ZA201704495B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3912981A1 (en) | 2014-09-17 | 2021-11-24 | Celgene Car Llc | Mk2 inhibitors and uses thereof |
| AU2018236286B2 (en) | 2017-03-16 | 2022-02-17 | Bristol-Myers Squibb Company | Forms and compositions of a MK2 inhibitor |
| KR20200130808A (en) | 2018-03-13 | 2020-11-20 | 가부시키가이샤 아데카 | Non-aqueous electrolyte secondary battery |
| WO2021211854A1 (en) * | 2020-04-16 | 2021-10-21 | Cai Gu Huang | Inhalable formulation of a solution containing tiotropium bromide |
| CN111647088B (en) * | 2020-06-29 | 2023-05-02 | 东北师范大学 | Cell penetration short peptide TAT-HNS-3 and application thereof to inflammatory diseases |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| BR8305562A (en) | 1982-10-08 | 1984-05-15 | Glaxo Group Ltd | DEVICE FOR GIVING MEDICINE TO PATIENTS AND PACKAGING |
| SE8603252L (en) | 1985-07-30 | 1987-01-31 | Glaxo Group Ltd | DEVICE FOR SUPPLYING MEDICINE TO PATIENTS |
| JPH05963A (en) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | Polypeptide composition |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US20080176790A1 (en) * | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
| EP2606903B1 (en) | 2007-01-10 | 2016-09-14 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therefor |
| WO2009021137A2 (en) | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
| AU2009322865B2 (en) * | 2008-10-20 | 2013-07-18 | Moerae Matrix, Inc. | Polypeptide for treating or preventing adhesions |
| AU2009324661A1 (en) | 2008-12-10 | 2011-07-07 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| US9890195B2 (en) | 2009-07-27 | 2018-02-13 | Purdue Research Foundation | MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
| EP2575855A4 (en) | 2010-05-24 | 2014-03-12 | Moerae Matrix Inc | Methods for treating or preventing vascular graft failure |
| WO2012142320A2 (en) * | 2011-04-12 | 2012-10-18 | Moerae Matrix Inc | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| US20140072613A1 (en) * | 2012-09-10 | 2014-03-13 | Cynthia Lander | Compositions and Methods for Treating Cutaneous Scarring |
| US9102015B2 (en) * | 2013-03-14 | 2015-08-11 | Siemens Energy, Inc | Method and apparatus for fabrication and repair of thermal barriers |
| RU2015148055A (en) * | 2013-04-11 | 2017-05-16 | Вандербилт Юниверсити | POLYPLEXES |
-
2016
- 2016-01-08 WO PCT/US2016/012650 patent/WO2016112292A1/en active Application Filing
- 2016-01-08 CA CA2972916A patent/CA2972916A1/en not_active Abandoned
- 2016-01-08 KR KR1020177021042A patent/KR20170102900A/en unknown
- 2016-01-08 MX MX2017008994A patent/MX2017008994A/en unknown
- 2016-01-08 EP EP16735478.6A patent/EP3242886A4/en not_active Withdrawn
- 2016-01-08 BR BR112017014737A patent/BR112017014737A2/en not_active Application Discontinuation
- 2016-01-08 AU AU2016205125A patent/AU2016205125A1/en not_active Abandoned
- 2016-01-08 JP JP2017536526A patent/JP2018502860A/en active Pending
- 2016-01-08 US US14/991,531 patent/US10087225B2/en not_active Expired - Fee Related
- 2016-01-08 CN CN201680005237.6A patent/CN107406489A/en active Pending
- 2016-01-08 RU RU2017128077A patent/RU2017128077A/en not_active Application Discontinuation
- 2016-01-08 SG SG11201705559RA patent/SG11201705559RA/en unknown
-
2017
- 2017-07-03 ZA ZA2017/04495A patent/ZA201704495B/en unknown
-
2018
- 2018-05-14 HK HK18106201.2A patent/HK1246807A1/en unknown
- 2018-08-21 US US16/106,504 patent/US20190031730A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3242886A1 (en) | 2017-11-15 |
| US20190031730A1 (en) | 2019-01-31 |
| CN107406489A (en) | 2017-11-28 |
| EP3242886A4 (en) | 2018-08-29 |
| CA2972916A1 (en) | 2016-07-14 |
| MX2017008994A (en) | 2018-09-18 |
| HK1246807A1 (en) | 2018-09-14 |
| JP2018502860A (en) | 2018-02-01 |
| WO2016112292A1 (en) | 2016-07-14 |
| AU2016205125A1 (en) | 2017-07-13 |
| RU2017128077A (en) | 2019-02-08 |
| BR112017014737A2 (en) | 2018-01-16 |
| KR20170102900A (en) | 2017-09-12 |
| RU2017128077A3 (en) | 2019-09-30 |
| US20160200782A1 (en) | 2016-07-14 |
| ZA201704495B (en) | 2019-01-30 |
| US10087225B2 (en) | 2018-10-02 |
| AU2016205125A2 (en) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259560A (en) | Inhibitors of the menin-mll interaction | |
| ZA201705527B (en) | TGF-ß INHIBITORS | |
| IL251051A0 (en) | Mk2 inhibitors and uses thereof | |
| GB201513010D0 (en) | Novel formulation | |
| HK1246807A1 (en) | Formulation of mk2 inhibitor peptides | |
| GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL284236A (en) | Modifications and uses of conotoxin peptides | |
| HK1251979A1 (en) | Peptide compositions and methods of use | |
| GB201501004D0 (en) | Inhibitors | |
| HK1257745A1 (en) | Peptide composition | |
| GB2540026B (en) | Fragment retentive coating formulation | |
| GB201506316D0 (en) | Novel peptide | |
| ZA201803032B (en) | Pharmaceutical compositions of dimethyl fumarate | |
| IL257803B (en) | Analogues of vdac1-derived peptides | |
| SG11201609739UA (en) | Derivatives of dolaproine-dolaisoleuine peptides | |
| GB201511255D0 (en) | Formulation | |
| GB201509891D0 (en) | Formulation | |
| HK1251593A1 (en) | Bace1 inhibitor peptides | |
| GB201520949D0 (en) | Inhibitors | |
| GB201504211D0 (en) | Use of peptides | |
| PT3280430T (en) | Use of qbp1 peptide for the inhibition of memory consolidation | |
| GB201502834D0 (en) | Composition of objects | |
| GB201506360D0 (en) | Novel peptide | |
| GB201508527D0 (en) | Novel formulation | |
| GB201504662D0 (en) | Formulation |